State-owned shot Kangmei Pharmaceuticals re-branding up and down Guang Pharmaceutical Group into the biggest winner?

On September 3rd, Comey Pharmaceuticals opened higher and lower.
close, ST Comm closed up 5.08 per cent at 3.1 yuan per share.
market capitalisation of the company is 15.419 billion.
Source: With Huashun State-owned, Kangmei Re-branding July 23, 2020, Kangmei Pharmaceuticals announced that the controlling shareholder Kangmei Industrial is planning major matters that may lead to a change in the company's control.
in view of the uncertainty of the matter, the shares will be suspended from the date of the announcement.
more than a month ago, Comey Pharmaceuticals officially resumed licensing on September 3.
And on the night before the resumption of trading, Kangmei Pharmaceuticals issued a number of announcements that the company's actual controller Ma Xingtian and his spouse Xu Dongxuan and Jieyang Yilin Pharmaceutical Investment Co., Ltd. (hereinafter referred to as "Yilin Investment") have signed a conditional entry into force of the Cooperation Agreement, Production and Operations Custody Agreement, Asset and Liabilities Custody and Disposal Agreement, the current custody period of 24 months after the effective date of the agreement.
At the same time, the controlling shareholder of the Company, Kangmei Industrial, intends to transfer its 1,487 million shares of the Company, corresponding to the voting rights corresponding to 29.90% of the Company's shares and the right to nominate and propose, unconditionally and irrevocablely to Yilin Investment.
once the resolution is considered and adopted at the shareholders' meeting, Yilin Investment will become a controlling shareholder of Comey.
yilin investment without a controlling shareholder and actual controller.
Enterprise inspection shows that Yilin Investment was established on August 18, 2020, with a registered capital of 20 million yuan, Jieyang City Investment and Construction Group Co., Ltd. holds 40% of its shares, Guangdong Province Jinsu Equity Trust Center Co., Ltd. and Guangzhou Shennon's Chinese Medicine Development Co., Ltd. hold 30% of the shares.
the previous suspension of Kangmei Pharmaceuticals, there are rumors that Guangdong state-owned is Kangmei Pharmaceuticals' largest rumored target.
today, the Guangdong SASAC is indeed one of its indirect shareholders.
also includes the China Development Bank, the State-owned Security Commission of Jieyang City, and the Guangzhou Municipal Government.
Jieyang City Investment and Construction Group's shareholders are mainly the State Development Bank, Jieyang City SASAC, the two holding 62.26 percent, 37.74 percent, respectively;
After Kangmei's announcement, it is worth noting that the Shanghai Stock Exchange issued a letter of inquiry, asking Kangmei to explain that Yilin Investment has no controlling shareholders and actual controllers, and that it guarantees the company's standardized operation and normal operation of the proposed measures.
and requested it to explain the management of the company's production and operation and disposal of assets and debts after the voting rights corresponding to the 29.9% shares of Yilin Investment Trustee, and to explain the impact of the arrangement on the independence of the listed company and the impact on the interests of other shareholders of the company, especially small and medium-sized shareholders, and the arrangements for its response.
the state-owned enterprises to take the lead, Guangzhou Pharmaceutical Group or become the biggest winner? Industry sources said that Yilin investment was established to invest in Kangmei Pharmaceuticals, from the company's shareholder background, or by the Guangdong Provincial Government to take the lead in the disposal, Kangmei Pharmaceuticals registered with the participation of the Municipal Government, the actual management of Kangmei or only Guangzhou Shennon's Chinese Medicine Development Co., Ltd.
, founder of Beijing Dingchen Pharmaceutical Management Consulting Center, told Sina Pharmaceuticals that it is not difficult to understand.
Previously, Kangmei Pharmaceuticals due to financial fraud, nearly 30 billion yuan of monetary funds "flying without wings", Kangmei Pharmaceuticals financial problems to be clarified, the relevant penalties are not in place, perhaps there is still a "hidden mine."
against this background, it is actually best to be taken over by state-owned companies and then managed by its controlling subsidiaries, which may be better able to take over and clean up the financial problems of Comey Pharmaceuticals than other private capital.
and the current pharmaceutical industry is one of the local pillar industries.
Intriguingly, the data show that Guangzhou Shennon's Chinese Medicine Development Co., Ltd., a wholly-owned subsidiary of Guang Pharmaceutical Group, was established on August 17, 2020, and is registered on the 3rd floor of the 1st floor of 65 Shamen North Street, Tsuen Wan District, Guangzhou City, with the legal representative as Liu Guowei.
the company's time was the day before Yilin's investment was established.
And Yilin Investment's senior executives and Shen Nong's executives repeat, such as Yilin Investment's directors, general managers and Shen nong's managers, executive directors are Liu Guowei, Yilin Investment another director Zhou Yunfeng, in Shennon's position as supervisor, as shown in the figure: Source: Tianye Check According to the agreement between the two sides, Kangmei Industrial, Kangmei Pharmaceuticals bear the relevant agreement under the income, risk, loss, obligations, debt, etc., Yilin Investment does not assume any responsibility.
and to cover the operating costs of this hosting, Comey Pharmaceuticals will have to pay a 4 million yuan custody fee to Yilin Investment every 6 months.
this calculation, Kangmei Pharmaceuticals need to pay 8 million yuan a year custody fees, Guang Pharmaceutical Group this deal is not a loss.
the future of the company's loss-making Kangmei, which sells real estate for live assets? Affected by the focus on the main industry, adjustment of business strategy, and the impact of the epidemic, Kangmei Pharmaceuticals half-yearly report showed that the company achieved revenue of 2.516 billion yuan during the reporting period, down 69.05 percent year-on-year, net profit of -1.423 billion yuan, down 1765 percent year-on-year.
, Comey Pharmaceuticals is under greater pressure to pay its debts.
first half of this year, Kangmei currency funds of 361 million yuan, consolidated statement caliber interest-bearing liabilities of 33.335 billion, the size of the stock debt is still large.
's main business for the production and sale of Chinese medicine tablets as the core, the implementation of the chinese medicine industry chain integrated operating model.
production and operation of products related to Chinese medicine tablets, Western medicine, health food and food, Chinese medicine, medical equipment and so on.
In order to further incumps assets and focus on the main business, Kangmei Health Industry Investment Co., Ltd., a wholly-owned subsidiary of Kangmei, signed a transfer agreement with Guangfa Fund, and Kangmei Subsidiary intends to sell its subsidiary to Zhangzhou A in Haizhu District, Guangzhou, for not more than 113 million yuan. District AH040248 lot and Guangzhou Haizhu District, Zhangzhou Internet Innovation Cluster across the municipal road link (10)-2 block of the two state-owned construction land use rights and its above-ground and underground buildings and/or construction projects under construction.
July 10, 2020, Kangmei Pharmaceuticals received a notification from the family of the actual controller, Mr. Ma Xingtian, who was coerced by the public security authorities on suspicion of illegal disclosure and non-disclosure of important information.
Comme announced that in order to solve the problem of capital occupation, fully protect the interests of the company and small and medium-sized shareholders, Ma Xingtian issued a "debt repayment commitment" to the company, Ma Xingtian intends to cash installments to repay the capital occupier non-operating occupation of all the company's funds, estimated to reach 9,481 million yuan.
after Kangmei Pharmaceuticals was taken over, how to continue to promote the matter also triggered the SSE inquiry.
industry speculated that Comey's original management might be exiting as the real controller changes.
face huge debt pressure, after the state-owned take-over, Kangmei Pharmaceuticals can turn around again? According to Sina Pharma, most people in the industry are optimistic about Kangmei's hosting this time.
believe that after thoroughly clarifying its financial problems, Comey is expected to continue to rely on its leading position in the Chinese medicine tablet industry, mature supply chain and downstream supplier system, such as a blood-stained resurrection.
.